Neocytolysis contributes to the anemia of renal disease.

Rice L, Alfrey CP, Driscoll T, Whitley CE, Hachey DL, Suki W
Am J Kidney Dis. 1999 33 (1): 59-62

PMID: 9915268 · DOI:10.1016/s0272-6386(99)70258-1

Neocytolysis is a recently described physiological process affecting the selective hemolysis of young red blood cells in circumstances of plethora. Erythropoietin (EPO) depression appears to initiate the process, providing the rationale to investigate its contributions to the anemia of renal disease. When EPO therapy was withheld, four of five stable hemodialysis patients showed chromium 51 (51Cr)-red cell survival patterns indicative of neocytolysis; red cell survival was short in the first 9 days, then normalized. Two of these four patients received oral 13C-glycine and 15N-glycine, and there was a suggestion of pathological isotope enrichment of stool porphyrins when EPO therapy was held, again supporting selective hemolysis of newly released red cells that take up the isotope (one patient had chronic hemolysis indicated by isotope studies of blood and stool). Thus, neocytolysis can contribute to the anemia of renal disease and explain some unresolved issues about such anemia. One implication is the prediction that intravenous bolus EPO therapy is metabolically and economically inefficient compared with lower doses administered more frequently subcutaneously.

MeSH Terms (13)

Adult Aged Anemia Cell Survival Erythrocytes Erythropoietin Hemolysis Humans Kidney Failure, Chronic Middle Aged Recombinant Proteins Terminology as Topic Time Factors

Connections (1)

This publication is referenced by other Labnodes entities:

Links